3B Blackbio DX Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 12, 2025, 12:13 am

Market Cap	1,312 Cr.
Current Price	1,528
High / Low	2,350/1,186
Stock P/E	27.5
Book Value	313
Dividend Yield	0.20 %
ROCE	25.8 %
ROE	19.4 %
Face Value	10.0
PEG Ratio	-1.51

Quick Insight

3B Blackbio DX Ltd, operating in the agro chemicals/pesticides sector, demonstrates solid financial health with a share price of ₹1,550 and a market capitalization of ₹1,330 Cr. The company's P/E ratio stands at 27.9, indicating potential growth opportunities. With an ROE of 19.4% and ROCE of 25.8%, the company efficiently utilizes its capital. A healthy OPM of 35.20% and a high ICR of 600.85x further underscore its profitability and liquidity. Additionally, the company's debt-free status, high reserves of ₹260 Cr, and a significant promoter holding of 41.29% provide a stable foundation for growth. Investors should consider 3B Blackbio DX Ltd as a promising investment option in the agrochemical sector.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for 3B Blackbio DX Ltd

Competitors of 3B Blackbio DX Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Epigral Ltd	8,020 Cr.	1,863	2,408/1,502	18.6	441	0.32 %	24.9 %	22.3 %	10.0
Dharmaj Crop Guard Ltd	1,085 Cr.	321	390/165	31.2	117	0.00 %	12.0 %	9.24 %	10.0
Bhaskar Agrochemicals Ltd	61.5 Cr.	118	148/55.2	15.8	34.1	0.00 %	21.3 %	24.7 %	10.0
Bhagiradha Chemicals & Industries Ltd	3,678 Cr.	284	448/260	134	53.9	0.05 %	7.44 %	4.91 %	1.00
Best Agrolife Ltd	967 Cr.	408	704/244	14.1	320	0.73 %	12.9 %	9.95 %	10.0
Industry Average	12,171.15 Cr	1,710.56		39.77	435.34	0.36%	15.26%	19.89%	7.25

All Competitor Stocks of 3B Blackbio DX Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	18.40	11.69	17.31	14.73	18.11	14.28	19.18	17.67	23.00	19.43	29.15	25.39	22.50
Expenses	12.48	6.51	8.13	7.42	10.65	7.84	11.39	8.80	13.12	8.48	12.98	10.32	14.58
Operating Profit	5.92	5.18	9.18	7.31	7.46	6.44	7.79	8.87	9.88	10.95	16.17	15.07	7.92
OPM %	32.17%	44.31%	53.03%	49.63%	41.19%	45.10%	40.62%	50.20%	42.96%	56.36%	55.47%	59.35%	35.20%
Other Income	1.87	1.24	1.96	2.88	1.15	2.96	2.75	2.63	4.19	3.69	3.44	3.01	4.94
Interest	-0.02	0.03	0.07	0.05	0.04	0.02	0.04	0.03	0.04	0.01	0.03	0.02	0.04
Depreciation	0.17	0.17	0.24	0.25	0.21	0.19	0.24	0.32	0.30	0.27	0.27	0.27	0.28
Profit before tax	7.64	6.22	10.83	9.89	8.36	9.19	10.26	11.15	13.73	14.36	19.31	17.79	12.54
Tax %	36.91%	24.12%	23.27%	22.04%	37.80%	21.55%	26.02%	23.68%	35.98%	21.31%	22.99%	24.17%	35.89%
Net Profit	4.82	4.72	8.31	7.72	5.19	7.21	7.58	8.51	8.79	11.30	14.87	13.49	8.04
EPS in Rs	5.53	5.39	11.20	8.96	7.72	9.71	10.46	10.16	10.33	12.97	17.07	15.61	9.79

Last Updated: May 31, 2025, 7:15 am

Below is a detailed analysis of the quarterly data for 3B Blackbio DX Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 22.50 Cr.. The value appears to be declining and may need further review. It has decreased from 25.39 Cr. (Dec 2024) to 22.50 Cr., marking a decrease of 2.89 Cr..
For Expenses, as of Mar 2025, the value is 14.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.32 Cr. (Dec 2024) to 14.58 Cr., marking an increase of 4.26 Cr..
For Operating Profit, as of Mar 2025, the value is 7.92 Cr.. The value appears to be declining and may need further review. It has decreased from 15.07 Cr. (Dec 2024) to 7.92 Cr., marking a decrease of 7.15 Cr..
For OPM %, as of Mar 2025, the value is 35.20%. The value appears to be declining and may need further review. It has decreased from 59.35% (Dec 2024) to 35.20%, marking a decrease of 24.15%.
For Other Income, as of Mar 2025, the value is 4.94 Cr.. The value appears strong and on an upward trend. It has increased from 3.01 Cr. (Dec 2024) to 4.94 Cr., marking an increase of 1.93 Cr..
For Interest, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
For Depreciation, as of Mar 2025, the value is 0.28 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Dec 2024) to 0.28 Cr., marking an increase of 0.01 Cr..
For Profit before tax, as of Mar 2025, the value is 12.54 Cr.. The value appears to be declining and may need further review. It has decreased from 17.79 Cr. (Dec 2024) to 12.54 Cr., marking a decrease of 5.25 Cr..
For Tax %, as of Mar 2025, the value is 35.89%. The value appears to be increasing, which may not be favorable. It has increased from 24.17% (Dec 2024) to 35.89%, marking an increase of 11.72%.
For Net Profit, as of Mar 2025, the value is 8.04 Cr.. The value appears to be declining and may need further review. It has decreased from 13.49 Cr. (Dec 2024) to 8.04 Cr., marking a decrease of 5.45 Cr..
For EPS in Rs, as of Mar 2025, the value is 9.79. The value appears to be declining and may need further review. It has decreased from 15.61 (Dec 2024) to 9.79, marking a decrease of 5.82.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 2:42 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	22	19	17	16	23	23	29	227	81	62	74	96
Expenses	21	18	16	14	18	16	20	77	44	33	41	46
Operating Profit	1	1	2	3	5	7	9	150	37	29	33	50
OPM %	6%	7%	9%	16%	23%	31%	32%	66%	46%	47%	44%	52%
Other Income	0	0	0	0	0	1	2	3	7	7	13	15
Interest	1	1	1	1	1	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	1	1	1	1	1	1	1
Profit before tax	0	0	0	1	5	7	10	152	43	35	44	64
Tax %	14%	23%	23%	19%	24%	25%	23%	25%	26%	27%	28%	25%
Net Profit	0	0	0	1	3	5	8	114	32	26	32	48
EPS in Rs	0.59	0.36	0.51	1.76	5.35	8.18	10.24	151.66	42.89	34.55	37.40	55.52
Dividend Payout %	0%	0%	0%	17%	9%	6%	7%	6%	24%	8%	8%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	200.00%	66.67%	60.00%	1325.00%	-71.93%	-18.75%	23.08%	50.00%
Change in YoY Net Profit Growth (%)	0.00%	-133.33%	-6.67%	1265.00%	-1396.93%	53.18%	41.83%	26.92%

3B Blackbio DX Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	18%
5 Years:	27%
3 Years:	6%
TTM:	30%

Compounded Profit Growth
10 Years:	70%
5 Years:	44%
3 Years:	14%
TTM:	48%

Stock Price CAGR
10 Years:	70%
5 Years:	26%
3 Years:	60%
1 Year:	27%

Return on Equity
10 Years:	29%
5 Years:	30%
3 Years:	17%
Last Year:	19%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:02 pm

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6	6	6	6	6	6	7	7	7	9	9	9
Reserves	4	4	4	5	12	16	25	125	146	185	214	260
Borrowings	7	8	8	9	6	6	4	2	3	2	1	0
Other Liabilities	7	7	6	6	6	8	9	59	37	19	24	27
Total Liabilities	24	25	24	26	30	36	45	194	192	214	248	296
Fixed Assets	4	4	3	3	4	4	4	5	7	8	7	7
CWIP	0	0	0	0	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	1	59	93	92	117	156
Other Assets	20	21	21	22	26	32	40	130	93	114	123	132
Total Assets	24	25	24	26	30	36	45	194	192	214	248	296

Below is a detailed analysis of the balance sheet data for 3B Blackbio DX Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
For Reserves, as of Mar 2025, the value is 260.00 Cr.. The value appears strong and on an upward trend. It has increased from 214.00 Cr. (Mar 2024) to 260.00 Cr., marking an increase of 46.00 Cr..
For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 27.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.00 Cr. (Mar 2024) to 27.00 Cr., marking an increase of 3.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 296.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 248.00 Cr. (Mar 2024) to 296.00 Cr., marking an increase of 48.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 7.00 Cr..
For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 39.00 Cr..
For Other Assets, as of Mar 2025, the value is 132.00 Cr.. The value appears strong and on an upward trend. It has increased from 123.00 Cr. (Mar 2024) to 132.00 Cr., marking an increase of 9.00 Cr..
For Total Assets, as of Mar 2025, the value is 296.00 Cr.. The value appears strong and on an upward trend. It has increased from 248.00 Cr. (Mar 2024) to 296.00 Cr., marking an increase of 48.00 Cr..

Notably, the Reserves (260.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	0	0	1	1	2	4	7	98	37	20	27	43
Cash from Investing Activity +	-0	-0	-0	-0	-1	-1	-1	-70	-28	15	-20	-34
Cash from Financing Activity +	0	-0	-1	-0	0	-1	1	-2	-15	-5	-4	-3
Net Cash Flow	0	-0	0	0	1	2	7	26	-6	30	3	6

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-6.00	-7.00	-6.00	-6.00	-1.00	1.00	5.00	148.00	34.00	27.00	32.00	50.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

No data available for the Financial Efficiency data table.

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoters	38.35%	38.35%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	41.29%
FIIs	1.47%	0.54%	1.23%	1.64%	1.64%	1.64%	2.11%	2.54%	3.06%	3.16%	3.38%	2.97%
DIIs	0.09%	0.08%	0.08%	0.08%	0.08%	0.00%	0.00%	0.00%	0.00%	0.82%	1.18%	1.89%
Public	60.09%	61.03%	60.26%	59.85%	59.85%	59.94%	59.47%	59.02%	58.50%	57.60%	56.99%	53.85%
No. of Shareholders	10,541	16,251	16,756	16,468	16,316	15,415	13,798	13,136	12,416	10,513	10,088	9,753

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	55.66	37.40	34.55	43.40	151.66
Diluted EPS (Rs.)	55.66	37.40	34.55	43.40	151.66
Cash EPS (Rs.)	56.93	38.70	35.77	43.88	152.82
Book Value[Excl.RevalReserv]/Share (Rs.)	313.27	263.15	261.50	229.69	197.92
Book Value[Incl.RevalReserv]/Share (Rs.)	313.27	263.15	261.50	229.69	197.92
Revenue From Operations / Share (Rs.)	112.59	86.51	82.54	107.65	302.66
PBDIT / Share (Rs.)	76.08	53.12	48.55	58.73	204.07
PBIT / Share (Rs.)	74.82	51.88	47.40	57.84	203.25
PBT / Share (Rs.)	74.69	51.74	47.13	57.69	202.94
Net Profit / Share (Rs.)	55.66	37.46	34.62	42.98	152.00
NP After MI And SOA / Share (Rs.)	55.61	37.46	34.62	42.98	152.00
PBDIT Margin (%)	67.57	61.40	58.81	54.56	67.42
PBIT Margin (%)	66.45	59.97	57.42	53.72	67.15
PBT Margin (%)	66.34	59.80	57.10	53.59	67.05
Net Profit Margin (%)	49.43	43.30	41.94	39.92	50.21
NP After MI And SOA Margin (%)	49.39	43.30	41.94	39.92	50.21
Return on Networth / Equity (%)	17.75	14.39	15.14	21.04	86.23
Return on Capital Employeed (%)	23.13	19.28	17.76	24.73	101.13
Return On Assets (%)	16.11	12.93	12.11	16.76	58.83
Long Term Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Total Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Asset Turnover Ratio (%)	0.35	0.32	0.30	0.13	0.38
Current Ratio (X)	7.11	7.04	8.05	4.82	2.76
Quick Ratio (X)	6.64	6.56	7.49	4.38	2.64
Inventory Turnover Ratio (X)	3.03	2.41	2.33	2.66	2.68
Interest Coverage Ratio (X)	600.85	365.87	183.32	413.58	669.53
Interest Coverage Ratio (Post Tax) (X)	440.55	259.05	131.73	303.65	499.68
Enterprise Value (Cr.)	1319.35	600.55	278.94	248.35	196.43
EV / Net Operating Revenue (X)	13.68	8.10	4.51	3.08	0.86
EV / EBITDA (X)	20.24	13.19	7.67	5.64	1.28
MarketCap / Net Operating Revenue (X)	14.36	8.90	5.04	3.17	0.94
Price / BV (X)	5.16	2.96	1.82	1.67	1.62
Price / Net Operating Revenue (X)	14.36	8.90	5.04	3.17	0.94
EarningsYield	0.03	0.04	0.08	0.12	0.53

After reviewing the key financial ratios for 3B Blackbio DX Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.66, marking an increase of 18.26.
For Diluted EPS (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.66, marking an increase of 18.26.
For Cash EPS (Rs.), as of Mar 25, the value is 56.93. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 56.93, marking an increase of 18.23.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 112.59. It has increased from 86.51 (Mar 24) to 112.59, marking an increase of 26.08.
For PBDIT / Share (Rs.), as of Mar 25, the value is 76.08. This value is within the healthy range. It has increased from 53.12 (Mar 24) to 76.08, marking an increase of 22.96.
For PBIT / Share (Rs.), as of Mar 25, the value is 74.82. This value is within the healthy range. It has increased from 51.88 (Mar 24) to 74.82, marking an increase of 22.94.
For PBT / Share (Rs.), as of Mar 25, the value is 74.69. This value is within the healthy range. It has increased from 51.74 (Mar 24) to 74.69, marking an increase of 22.95.
For Net Profit / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 55.61. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.61, marking an increase of 18.15.
For PBDIT Margin (%), as of Mar 25, the value is 67.57. This value is within the healthy range. It has increased from 61.40 (Mar 24) to 67.57, marking an increase of 6.17.
For PBIT Margin (%), as of Mar 25, the value is 66.45. This value exceeds the healthy maximum of 20. It has increased from 59.97 (Mar 24) to 66.45, marking an increase of 6.48.
For PBT Margin (%), as of Mar 25, the value is 66.34. This value is within the healthy range. It has increased from 59.80 (Mar 24) to 66.34, marking an increase of 6.54.
For Net Profit Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 10. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 49.39. This value exceeds the healthy maximum of 20. It has increased from 43.30 (Mar 24) to 49.39, marking an increase of 6.09.
For Return on Networth / Equity (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has increased from 14.39 (Mar 24) to 17.75, marking an increase of 3.36.
For Return on Capital Employeed (%), as of Mar 25, the value is 23.13. This value is within the healthy range. It has increased from 19.28 (Mar 24) to 23.13, marking an increase of 3.85.
For Return On Assets (%), as of Mar 25, the value is 16.11. This value is within the healthy range. It has increased from 12.93 (Mar 24) to 16.11, marking an increase of 3.18.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.35. It has increased from 0.32 (Mar 24) to 0.35, marking an increase of 0.03.
For Current Ratio (X), as of Mar 25, the value is 7.11. This value exceeds the healthy maximum of 3. It has increased from 7.04 (Mar 24) to 7.11, marking an increase of 0.07.
For Quick Ratio (X), as of Mar 25, the value is 6.64. This value exceeds the healthy maximum of 2. It has increased from 6.56 (Mar 24) to 6.64, marking an increase of 0.08.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.03. This value is below the healthy minimum of 4. It has increased from 2.41 (Mar 24) to 3.03, marking an increase of 0.62.
For Interest Coverage Ratio (X), as of Mar 25, the value is 600.85. This value is within the healthy range. It has increased from 365.87 (Mar 24) to 600.85, marking an increase of 234.98.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 440.55. This value is within the healthy range. It has increased from 259.05 (Mar 24) to 440.55, marking an increase of 181.50.
For Enterprise Value (Cr.), as of Mar 25, the value is 1,319.35. It has increased from 600.55 (Mar 24) to 1,319.35, marking an increase of 718.80.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.68. This value exceeds the healthy maximum of 3. It has increased from 8.10 (Mar 24) to 13.68, marking an increase of 5.58.
For EV / EBITDA (X), as of Mar 25, the value is 20.24. This value exceeds the healthy maximum of 15. It has increased from 13.19 (Mar 24) to 20.24, marking an increase of 7.05.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 2.96 (Mar 24) to 5.16, marking an increase of 2.20.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of 3B Blackbio DX Ltd as of August 11, 2025 is: 1,338.56

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of August 11, 2025, 3B Blackbio DX Ltd is Overvalued by 12.40% compared to the current share price 1,528.00

Intrinsic Value of 3B Blackbio DX Ltd as of August 11, 2025 is: 1,094.85

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of August 11, 2025, 3B Blackbio DX Ltd is Overvalued by 28.35% compared to the current share price 1,528.00

Last 5 Year EPS CAGR: -18.21%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in 3B Blackbio DX Ltd:
1. Net Profit Margin: 49.43%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.13% (Industry Average ROCE: 15.26%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 17.75% (Industry Average ROE: 19.89%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 440.55
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 6.64
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 27.5 (Industry average Stock P/E: 31.49)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

3B BlackBio Dx Ltd. is a Public Limited Listed company incorporated on 27/05/1972 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN) is L24211MP1972PLC001131 and registration number is 001131. Currently Company is involved in the business activities of Manufacture of pesticides and other agrochemical products. Company's Total Operating Revenue is Rs. 90.53 Cr. and Equity Capital is Rs. 8.57 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Agro Chemicals/Pesticides	7-C, Industrial Area, Govindpura, Bhopal Madhya Pradesh 462023	info@kilpest.com http://www.kilpest.com

Management
Name	Position Held
Mr. Dhirendra Dubey	Chairman & Managing Director
Mr. N K Dubey	Whole Time Director
CA. Shabbar Husain	Independent Director
Mr. Abdul Moin Khan	Independent Director
Mrs. Mithala Dubey	Director
Mr. Harihar Prasad Thapak	Independent Director

FAQ

What is the intrinsic value of 3B Blackbio DX Ltd?

3B Blackbio DX Ltd's intrinsic value (as of 11 August 2025) is ₹1338.56 which is 12.40% lower the current market price of 1,528.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,312 Cr. market cap, FY2025-2026 high/low of 2,350/1,186, reserves of 260 Cr, and liabilities of 296 Cr.

What is the Market Cap of 3B Blackbio DX Ltd?

The Market Cap of 3B Blackbio DX Ltd is 1,312 Cr..

What is the current Stock Price of 3B Blackbio DX Ltd as on 11 August 2025?

The current stock price of 3B Blackbio DX Ltd as on 11 August 2025 is 1,528.

What is the High / Low of 3B Blackbio DX Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of 3B Blackbio DX Ltd stocks is 2,350/1,186.

What is the Stock P/E of 3B Blackbio DX Ltd?

The Stock P/E of 3B Blackbio DX Ltd is 27.5.

What is the Book Value of 3B Blackbio DX Ltd?

The Book Value of 3B Blackbio DX Ltd is 313.

What is the Dividend Yield of 3B Blackbio DX Ltd?

The Dividend Yield of 3B Blackbio DX Ltd is 0.20 %.

What is the ROCE of 3B Blackbio DX Ltd?

The ROCE of 3B Blackbio DX Ltd is 25.8 %.

What is the ROE of 3B Blackbio DX Ltd?

The ROE of 3B Blackbio DX Ltd is 19.4 %.

What is the Face Value of 3B Blackbio DX Ltd?

The Face Value of 3B Blackbio DX Ltd is 10.0.